Protein Blends (Soy, Whey and Casein) for Muscle Synthesis

October 3, 2019 updated by: DuPont Nutrition and Health

A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown

Soy protein is a high quality, plant-based protein that is comparable to milk, meat and eggs. Soy protein has a digestion rate (intermediate) compared to whey (fast) and casein (slow). This intermediate rate may allow soy protein to have an extended window of muscle protein synthesis that has not been monitored in previous studies. While most of the sports nutrition "recovery" products are dairy-based protein blends (high in branched-chain amino acids), soy protein offers additional benefits that can make an important contribution to these types of sports nutrition products. Soy protein contains approximately 300% more arginine and 30% more glutamine compared to whey protein and these two amino acids may bring additional benefits (immunity and hydration, respectively) to athletes. A "blend" of high-quality proteins (soy and dairy) may be the optimal sports nutrition product for athletes to consume following training.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

19

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Galveston, Texas, United States, 77555
        • UTMB General Clinical Research Center, located in the John Sealy Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion:

  1. Age 18-35 yrs
  2. Stable body weight for at least 1 year

Exclusion criteria will be:

  1. Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
  2. Significant heart, liver, kidney, blood, or respiratory disease
  3. Peripheral vascular disease
  4. Diabetes mellitus or other untreated endocrine disease
  5. Active cancer (all groups) and history of cancer (groups potentially randomizable to rapamycin)
  6. Acute infectious disease or history of chronic infections (e.g. TB, hepatitis, HIV, herpes)
  7. Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
  8. Alcohol or drug abuse
  9. Tobacco use (smoking or chewing)
  10. Malnutrition (BMI < 20 kg/m2, hypoalbuminemia, and/or hypotransferrinemia)
  11. Obesity (BMI > 30 kg/m2)
  12. Low hemoglobin levels (below normal values)
  13. Food allergies
  14. Taking dietary supplements such as green tea, etc.
  15. Currently on a high-soy diet (consuming >2 servings of soy per day)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Whey Protein Isolate
Single intake of approximately 20 grams of total protein
Experimental: Protein Blend (soy, whey and casein)
Single intake of approximately 20 grams of total protein

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle Protein Synthesis or Fractional synthesis rate (FSR)
Time Frame: baseline, 3 hours, 5 hours
The fractional synthesis rate (FSR) of mixed muscle proteins will be calculated from the incorporation rate of L-[ring-13C6]Phenylalanine into the mixed muscle proteins, and the free-tissue phenylalanine enrichment.
baseline, 3 hours, 5 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
oxidative and inflammatory markers
Time Frame: baseline, 3 hours, 5 hours
Proteins will be assessed that are markers of oxidative damage and inflammation (NFkB, IL-1, IL-6) and proteolysis (MuRF, MAFBx).
baseline, 3 hours, 5 hours
Phosphorylation of protein in muscle protein signaling pathways
Time Frame: baseline, 3 hours, 5 hours
Phosphorylation of mTOR, 4E-BP1, S6K1, S6, and eEF2 will be measured using Western blot techniques as previously described.
baseline, 3 hours, 5 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Ratna Mukherjea, PhD, Solae, LLC
  • Principal Investigator: Mark B Cope, PhD, Solae, LLC
  • Principal Investigator: Blake B Rasmussen, PhD, UTMB

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Actual)

August 1, 2012

Study Completion (Actual)

March 1, 2013

Study Registration Dates

First Submitted

May 19, 2011

First Submitted That Met QC Criteria

May 20, 2011

First Posted (Estimate)

May 23, 2011

Study Record Updates

Last Update Posted (Actual)

October 7, 2019

Last Update Submitted That Met QC Criteria

October 3, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • CRC-D-176

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Synthesis

Clinical Trials on Protein Blend

3
Subscribe